新辅助放化疗后改良整块食管切除术与标准切除术的比较
本研究回顾2006—2018年因食管腺癌接受新辅助放化疗后行食管切除术的患者,比较右胸改良整块切除术与标准切除术的结局。整块切除组切缘阳性率更低、淋巴结清扫数目更多, multivariable分析显示无进展生存延长,且术后并发症无差异。
要点
- 整块切除组切缘阳性率2%,标准切除组7%(P = .026)。
- 整块切除淋巴结清扫中位数27枚,标准切除22枚(P < .001)。
- 整块切除与更长无进展生存相关(HR 0.74;P = .041),并发症无差异。
核心结论
- 新辅助放化疗后行整块食管切除术可改善局部区域疾病控制,且不增加并发症。
研究设计与样本
- 回顾性研究,纳入2006—2018年因食管腺癌接受新辅助放化疗后行食管切除术的患者,共604例,其中133例(22%)接受改良整块食管切除术,其余接受标准食管切除术。
主要发现
- 切缘阳性在标准切除组为471例中35例(7%),整块切除组为133例中3例(2%)(P = .026)。
- 整块切除组淋巴结清扫数目中位数为27枚(四分位距22—36),标准切除组为22枚(四分位距17—28),P < .001。
- 多因素分析显示整块切除与延长的无进展生存相关(风险比0.74;P = .041)。
- 标准切除与整块切除的3年无局部区域复发率分别为78%和90%(P = .044)。
- 心肺、胃肠、伤口并发症以及漏和乳糜胸方面无差异。
临床怎么用
- 对于接受新辅助放化疗的食管腺癌患者,可考虑采用改良整块食管切除术以提高局部区域控制且不增加并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgeons have shifted away from the practice of en bloc esophagectomy, particularly in the era of neoadjuvant therapies. Although some still advocate for this radical approach, contemporary data establishing its superiority are sparse. We hypothesized that a more complete, radical resection could be completed in the setting of chemoradiation without adding morbidity. METHODS: Patients undergoing esophagectomy after neoadjuvant chemoradiation for esophageal adenocarcinoma from 2006-2018 were evaluated. Outcomes after right transthoracic en bloc esophagectomy were compared with standard esophagectomy to determine the impact on outcomes. A Cox proportional hazard model was evaluated, and logistic regression was performed to determine the impact of en bloc resection on postoperative morbidity. RESULTS: A total of 604 patients were identified, including 133 (22%) who underwent modified en bloc esophagectomy. Positive margins were most likely to occur in standard esophagectomy (35 of 471, 7%) vs en bloc (3 of 133, 2%) (P = .026). En bloc resection yielded a greater lymph node harvest (27; interquartile range, 22-36), as compared to standard esophagectomy (22; interquartile range, 17-28), P < .001. Multivariable analysis demonstrated prolonged progression-free survival with en bloc resection (hazard ratio, 0.74; P = .041), with 3-year freedom from locoregional recurrences of 78% and 90% for standard and en bloc approaches (P = .044). There were no differences in cardiopulmonary, gastrointestinal, or wound complications, as well as leak or chylothorax. CONCLUSIONS: Our experience demonstrates improved locoregional disease control with en bloc esophagectomy, with equivalent morbidity. Although these results may be multifactorial, including adequate clearance of both primary tumor and nodal micrometastases, this approach is safe and feasible.
引用
- Corsini EM, Mitchell KG, Zhou N, et al. Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg. 2020. PMID: 32857997. doi:10.1016/j.athoracsur.2020.06.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。